Efmarodocokin alfa在健康志愿者和溃疡性结肠炎患者中的剂量递增随机研究
这项随机1b期研究在健康志愿者(n=32)和溃疡性结肠炎患者(n=24)中评估了efmarodocokin alfa(UTTR1147A)每2周或每4周静脉给药12周的安全性、药代动力学和药效学。最常见不良事件为靶向性、可逆的皮肤反应;90 μg/kg每2周组出现剂量限制性皮肤不良事件。生物标志物证实结肠上皮IL-22R通路激活,临床缓解在活性治疗组为5/18、安慰剂组为0/6。
要点
- 最常见不良事件为靶向性、可逆的皮肤反应(干燥、红斑、瘙痒)。
- 90 μg/kg每2周组出现剂量限制性非严重皮肤不良事件(健康志愿者n=2,患者n=1)。
- 临床缓解:活性治疗组5/18 vs 安慰剂组0/6;临床应答:活性治疗组7/18 vs 安慰剂组1/6。
核心结论
- Efmarodocokin alfa在健康志愿者和患者中具有足够的安全性和药代动力学特征。
- 生物标志物数据证实结肠上皮IL-22R通路激活。
- 结果支持进一步研究这一非免疫抑制性潜在炎症性肠病治疗药物。
研究设计与样本
- 随机1b期研究,评估efmarodocokin alfa重复静脉给药的安全性、耐受性、药代动力学和药效学。
- 健康志愿者n=32,溃疡性结肠炎患者n=24;剂量30-90 μg/kg,每2周或每4周给药一次,持续12周;每个队列活性药物:安慰剂=6:2。
主要发现
- 最常见不良事件为靶向性、可逆的皮肤反应(干燥、红斑和瘙痒)。
- 剂量限制性非严重皮肤不良事件(严重皮肤干燥、红斑、脱屑和不适)见于90 μg/kg每2周组(健康志愿者n=2;患者n=1)。
- 药代动力学在各剂量水平总体呈剂量比例,但相同剂量下患者药物暴露低于健康志愿者。
- 活性治疗诱导了血清IL-22生物标志物和结肠活检中IL-22反应基因,微生物群组成变化与基线菌群失调逆转一致。
- 临床应答:活性治疗组7/18 vs 安慰剂组1/6;临床缓解:活性治疗组5/18 vs 安慰剂组0/6。
局限性
- 作为1b期研究,疗效终点仅为探索性。
- 结果支持进一步研究这一非免疫抑制性潜在炎症性肠病治疗药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interleukin-22 cytokine (IL-22) has demonstrated efficacy in preclinical colitis models with non-immunosuppressive mechanism of action. Efmarodocokin alfa (UTTR1147A) is a fusion protein agonist that links IL-22 to the crystallisable fragment (Fc) of human IgG4 for improved pharmacokinetic characteristics, but with a mutation to minimise Fc effector functions. METHODS: This randomised, phase 1b study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat intravenous dosing of efmarodocokin alfa in healthy volunteers (HVs; n=32) and patients with ulcerative colitis (n=24) at 30-90 µg/kg doses given once every 2 weeks or monthly (every 4 weeks) for 12 weeks (6:2 active:placebo per cohort). RESULTS: The most common adverse events (AEs) were on-target, reversible, dermatological effects (dry skin, erythema and pruritus). Dose-limiting non-serious dermatological AEs (severe dry skin, erythema, exfoliation and discomfort) were seen at 90 μg/kg once every 2 weeks (HVs, n=2; patients, n=1). Pharmacokinetics were generally dose-proportional across the dose levels, but patients demonstrated lower drug exposures relative to HVs at the same dose. IL-22 serum biomarkers and IL-22-responsive genes in colon biopsies were induced with active treatment, and microbiota composition changed consistent with a reversal in baseline dysbiosis. As a phase 1b study, efficacy endpoints were exploratory only. Clinical response was observed in 7/18 active-treated and 1/6 placebo-treated patients; clinical remission was observed in 5/18 active-treated and 0/6 placebo-treated patients. CONCLUSION: Efmarodocokin alfa had an adequate safety and pharmacokinetic profile in HVs and patients. Biomarker data confirmed IL-22R pathway activation in the colonic epithelium. Results support further investigation of this non-immunosuppressive potential inflammatory bowel disease therapeutic. TRIAL REGISTRATION NUMBER: NCT02749630.
引用
- Wagner F, Mansfield JC, Lekkerkerker AN, et al. Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis. Gut. 2023. PMID: 36732049. doi:10.1136/gutjnl-2022-328387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。